Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients With Progressive Multiple Sclerosis

NCT05054140 is registered in ClinicalTrials.gov with Immunic AG as lead sponsor.

NCT NCT05054140
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05054140 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients With Progressive Multiple Sclerosis
Lead sponsor
Immunic AG
Phase
Phase 2
Overall status
Unknown status
Start date
September 30, 2021
Completion date
January 7, 2025
Enrollment
450 (estimated)
Sites
73

Conditions

As the registry lists them; a condition with its own page is linked.

multiple sclerosis